Multiple myeloma was once considered a disease with few good treatment options and a poor prognosis. Today, in many cases, it can be managed for years or even decades. “When I first started seeing ...
Not a day goes by in clinic without a patient asking about the recent New York Times article on multiple myeloma: "Doc, is there really a cure now? I want this treatment." The article was boldly ...
CAR T-cell therapy modifies a patient's immune cells to target cancer, offering potential cures for blood cancers like lymphoma and myeloma. Up to 40% of lymphoma patients may achieve remission after ...
Digital xrays of both hands showing severe rheumatoid arthritis affecting both wrists and hands. Deformities limiting movement and associated with pain. A study published in the Journal of Immunology ...
Bicistronic CD19/CD22-directed CAR-T cell therapy achieved high remission rates and durable responses in pediatric B-ALL patients. One-year EFS and OS rates were 75.5% and 93.5%, respectively, with ...
Chimeric antigen receptor T-cell therapy targeting CD19 is highly effective for inducing remission among patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Despite that, 50% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results